A cancer patient has died after receiving an “unlicensed” version of a prostate cancer chemotherapy drug. Three other patients also needed hospital treatment. East Midlands drug manufacturer Sciensus admitted to administering an unlicensed version of Cabazitaxel to four prostate cancer patients. The UK healthcare products regulatory agency (MHRA) said it […]